Sales of a new portable CT scanner helped Analogic post recordrevenues and earnings for its fourth quarter and fiscal 1996 (end-July).Analogic also saw gains in other areas of its medical technologybusiness, according to officials with the Peabody, MA,
Sales of a new portable CT scanner helped Analogic post recordrevenues and earnings for its fourth quarter and fiscal 1996 (end-July).Analogic also saw gains in other areas of its medical technologybusiness, according to officials with the Peabody, MA, vendor.
For the year, Analogic posted revenue of $230.5 million, up10% compared with sales of $208.8 million the year before. Netincome for 1996 stood at $13.1 million, up from $12.7 millionin fiscal 1995.
Despite the year-over-year gains, it was in the fourth quarterthat Analogic saw real growth. Revenues for the most recent periodwere a record $70.4 million, up 25% compared with $56.3 millionin the same period last year. Net income grew to $5.9 million,compared with $4.2 million in the fourth quarter of 1995.
The revenue growth is due to higher sales in Analogic's medicaltechnology business, according to senior vice president and treasurerJohn Tarello. In particular, Analogic experienced strong fourth-quartersales of a portable CT scanner that went into production in January,Tarello said.
Analogic has licensed the system to Philips Medical Systems,which sells the unit in two versions as Tomoscan/M and Tomoscan/EG(SCAN 2/15/95). Philips debuted the scanner to the Asian marketat the International Congress of Radiology meeting in Beijinglast June (SCAN 7/17/96).
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.